Q-Line Biotech Ltd Guidance Report - SOIC x StockScans Report
as of Nov 2026
- DRHP working capital assumptions - debtors at 120-127 days
Partial - The DRHP assumed debtor holding days of 120 for FY 2025-26 and 127 for FY 2026-27. At the Q2 FY27 call, an analyst cited FY26 receivable days at 134 and the CFO stated receivables are currently between 120 to 150 days; the government receivable cycle is 4 to 5 months. No FY27 figure is disclosed yet.
- Unit 4 (C-42) operational - FY 2025-26
Delivered - The DRHP stated the new Lucknow reagents facility (C-42, Amausi Industrial Area) would become operational and commence commercial production in FY 2025-26. Unit 4 commenced operations in February 2026, within FY26, and was commissioned and capitalized as the company's largest Lucknow facility.
- CDMO operations - Selectra Pro M and Microlab 300 for export
Pending - Filings stated the intent to initiate CDMO operations manufacturing Selectra Pro M and Microlab 300 instruments for export to the principal company under an exclusive technical collaboration. At the Q2 FY27 call, operations had not yet commenced; the company was working towards commencing them, with a confirmed import order of around €2.3 million received.
- Certificate on Utilisation of Issue Proceeds - submitted with H1 FY27 results
Partial - Filings committed to submitting the Certificate on Utilisation of Issue Proceeds with the financial results for the half year ending 30 September 2026. The certificate was confirmed with NSE on 1 July 2026, but the monitoring agency answered "No" on whether all utilisation matches the Offer Document after Rs. 22.97 crore was moved pre-deployment.
- Listing on NSE Emerge - within three working days of issue closing
Delivered - The DRHP committed to listing and commencement of trading on NSE Emerge within three working days of Issue Closing. Equity shares were listed on NSE Emerge on 29 May 2026, raising Rs. 214.48 crores through a fresh issuance of 62,53,000 equity shares.
- Boule license agreement - 25% reduction in license/royalty payable
Delivered - Filings announced an Amended and Restated License Agreement with Boule Medical AB with rationalised purchase commitments, revised fees and volume-linked benefits, over an initial five-year term. A 25% reduction in license/royalty payable by Q-Line to Boule was agreed, effective from 01st July 2026.
- IPO proceeds utilization - Rs 90 crore toward repayment of borrowings
On track - The DRHP earmarked ₹90 crore of IPO proceeds (total ₹214.48 crore) toward repayment/pre-payment of borrowings. Per CA and management certificates, Rs. 9.50 crore was utilised towards working capital and Rs. 13.47 crore towards repayment/prepayment of borrowings, though Rs. 22.97 crore was transferred pre-deployment in a flagged deviation.
- Clinical Chemistry Reagents at Unit 4 - commercial production by Q2 FY27
Partial - Filings guided full-scale commercial production of Clinical Chemistry Reagents at Unit 4 by Q2 FY27, contingent on regulatory approvals. Unit 4 product licenses rose from 9 (30 September 2026) to 36 (5 November 2026); approvals took longer than anticipated, and C-42 output is moving to 35,000-40,000 kits per month.
- FY28 revenue growth - 25-30%
Pending - At the Q2 FY27 call, the CFO guided to a similar 25-30% revenue growth for FY28, "for now". No FY28 revenue read yet.
- QCOM-5 autoloader (SKD) launch - November 2026
Pending - At the Q2 FY27 call (Sep 2026), CFO Meenal Gupta said the QCOM-5 autoloader, on SKD basis, was "about to launch in probably November". As of today (14 Nov 2026), no cited source confirms the launch; Q-Count 3 & Q-Count 5 analyzers (SKD) are shown commercialized, but the autoloader outcome is absent from the sources.
- Reagent revenue share - 65-70% long term
Delivered - At the Q2 FY27 call, the CEO guided reagents to contribute around 65-70% of revenue long term. H1 FY27 product mix shows Reagents at 72% (Instruments 21%, Consumables 6%, Services 1%), up from 63% in H1 FY26, already above the target.
- Instrument sales value - stable vs FY26
On track - At the Q2 FY27 call, the CEO guided instrument sales value roughly stable vs last year - no de-growth but no high growth - supported by CDMO export, trade sales and pending government orders. H1 FY27 instrument revenue declined 29.71% (FY26 Rs 83 Cr; H1FY27 Rs 32 Cr) due to consignee non-availability.
- HB meter commercial invoices - by end of October 2026
Partial - At the Q2 FY27 call, the CEO guided commercial invoices for the HB meter by the end of October 2026. The HB meter received CDSCO NOD and is commercially launched, but the instrument is shown under development in pipeline status with no invoice confirmation disclosed.
- Chemiluminescence segment launch - last quarter of FY27
On track - At the Q2 FY27 call, the CEO guided the chemiluminescence segment launch in the last quarter of FY27, with CDSCO NOD already received. NOD has been received for more than 25 to 30 products, with a few CDSCO approvals for the instrument still awaited and no launch yet.
- Hidalgo revenue - \~Rs 130 crores for FY27
Pending - At the Q2 FY27 call, the CFO guided Hidalgo revenue of about Rs 130 crores for FY27 with margins improving as it moves from SKD to manufacturing. Hidalco revenue rose from Rs 50.91 crore (2024) to almost Rs 108 crore in FY26 with H1 EBITDA around Rs 6 crore; no FY27 revenue figure disclosed yet.
- R&D spend - more than Rs 2.5-3 crores every year
On track - At the Q4 FY26 call, Ajay Mahanty committed the company spends "more than INR2.5 crores to INR3 crores" on R&D every year. FY26 spend was more than INR2.5 crores in the biological segment and around INR5 crores total including equipment, maintained at \~1% of revenue; no FY27 figure yet.
- Microlab 300 launch - during FY27
Delivered - At the Q4 FY26 call, the CEO expected a launch of Microlab 300 during FY27. The Make in India Microlab 300 semi-auto analyzer was commercialized in October 2026 with a few units sold and more expected in H2.
- No major capex over next two years
Pending - At the Q4 FY26 call, the CFO stated no major capex is expected over the next two years, with the \~15 crores CWIP facility used as a warehouse for now. CWIP stood at Rs 19.31 crores for FY26 and H1 FY27 investing cash flow was -Rs 110 Cr; no guidance revision disclosed.
- Unit 4 revenue enablement - 3x to 4x of current reagent/CDMO revenue by FY30
On track - At the Q4 FY26 call, management expected Unit 4 to enable 3x to 4x of current reagent/CDMO revenue by "maybe FY30"; later revised to guidance of at least Rs 150-160 crore from C42 in FY27 and Rs 250-300 crore in FY28. Unit 4 commenced February 2026; licenses rose from 9 to 36 by 5 November 2026; no FY27 revenue read yet.
- No corporate guarantees in future
Pending - At the Q4 FY26 call, the CFO committed the company will not give any corporate guarantees in future, with existing guarantees being wound up and no timelines given. No disclosure in our record of new guarantees issued or existing ones wound up.
- B2G vs trade mix - 50-50 by end of 2028
On track - At the Q4 FY26 call, the CFO guided the B2G vs trade mix from 65/35 to 50-50 "by the end of 28"; later revised toward 30% government / 70% private from an FY29 perspective. H1 FY27 mix was Government 69% / Private 31%, with trade growing 20.13% and government stable YoY.
- EBITDA margin - maintain \~28% in FY27
On track - At the Q4 FY26 call, the CFO guided EBITDA margins slightly better than FY26 levels; at Q2 FY27 he guided to maintaining \~28% for FY27. H1 FY27 EBITDA margin improved to 26% vs 25.1% in H1 FY26 against FY26's 28.7%; H2 is seasonally stronger with 4-5 crores of interest savings expected.
- Receivable days - maintain within 90-120 days
Pending - At the Q4 FY26 call, the CFO guided receivable days to be maintained within 90 to 120 days going forward, from a current 120 to 150. The government receivable cycle is currently 4 to 5 months; no FY27 receivable days figure disclosed in our record.
- Working capital days - \~100 days going forward
Pending - At the Q4 FY26 call, the CFO guided working capital days of about 100 days going forward; at Q2 FY27 he guided \~30 days of improvement by end FY27 and 60-90 days as CDMO/export kick in in FY28. The government receivable cycle is 4 to 5 months and H1 FY27 operating cash flow was -Rs 9 Cr; no working capital days figure disclosed.
- CDMO instrument gross margins - 25%+
Pending - At the Q4 FY26 call, Y.S. Prabhakara guided CDMO instrument gross margins of 25% plus, up about 10 percentage points vs 10-15% retained domestically; at Q2 FY27 the CEO guided at least 25-30%. No CDMO margin read disclosed in our record.
- CDMO revenue - \~Rs 10 crores in FY27
On track - At the Q4 FY26 call, management targeted CDMO revenue of about INR10 crores in FY27, with traction expected in Q3 and Q4. CDMO operations for Selectra Pro M and Microlab 300 are being commenced with a confirmed import order worth around €2.3 million; no FY27 CDMO revenue recognized yet.
- Export revenue growth - \~5x in FY27
On track - At the Q4 FY26 call, management guided exports of more than 5x in FY27 versus INR1.2 crores earned in FY26, excluding CDMO; later revised to caution that West Asia geopolitical uncertainties may delay the pace. H1 FY27 export mix was 0.3% (\~Rs 0.46 crores), but a €2.3 million order was received and products registered in 10 to 11 countries.
- Total instrument installations - 2,000+ in FY27
Pending - At the Q4 FY26 call, management guided to more than 2,000 total instrument installations in the coming year, including 1,500 to 1,800 in India. H1 FY27 instrument revenue declined 29% on consignee non-availability; the company historically places 1,200 to 1,300 instruments a year, with no FY27 installation count disclosed.
- Selectra unit installations - 300-400 additional units in FY27
Pending - At the Q4 FY26 call, Ajay Mahanty committed to installing another 300 to 400 Selectra units in FY27. Selectra Pro M crossed an installation base of more than 1,550 instruments, with more than 450 installed in FY26 and the plant having produced over 1,400 analyzers; no FY27-specific count disclosed.
- Unit 4 (C-42) capacity utilization - 25-30% by end of FY27
On track - At the Q4 FY26 call, the CFO guided utilizing about 25% to 30% of Unit 4 capacity by end of FY27, later revised to around 25-30% of Plant A and B by 27th March. Licenses rose from 9 to almost 36 and kit output is moving to 35,000-40,000 kits per month; no utilization percentage disclosed yet.
- FY27 reagent revenue growth - 30-40%
On track - At the Q4 FY26 call, management expected reagent revenue to grow 30% to 35% in FY27, also stated as a 35% to 40% increase from manufactured reagents. H1 FY27 reagent business grew 19.23% (FY26 Rs 238 Cr; H1FY27 Rs 109 Cr), trailing the target with H2 seasonally stronger.
- FY27 consolidated revenue growth - 30-35% YoY
On track - At the Q4 FY26 call, CFO Meenal Gupta targeted consolidated revenue growth of approximately 30% to 35% for FY27; at Q2 FY27 this was revised down to 25-30%, with management "very confident" on Rs 400 crore for FY27. H1 FY27 revenue was Rs 152 crores vs Rs 143 crores, growth of 5.83%, against FY26 revenue of Rs 342 crores and H2 typically 60 to 70% of the year.